A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

To target mechanisms critical for multiple myeloma (MM) plasma cell adaptations to genomic instabilities and further sustain MM cell killing, we here specifically trigger DNA damage response (DDR) in MM cells by a novel BCMA antibody drug conjugate (ADC) delivering the DNA cross-linking PBD dimer te...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leukemia
Egile Nagusiak: Xing, Lijie, Lin, Liang, Yu, Tengteng, Li, Yuyin, Cho, Shih-Feng, Liu, Jiye, Wen, Kenneth, Hsieh, Phillip A, Kinneer, Krista, Munshi, Nikhil, Anderson, Kenneth C, Tai, Yu-Tzu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7392808/
https://ncbi.nlm.nih.gov/pubmed/32060401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0745-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak